

Supplemental Online Content

Proudman D, Miller A, Nellesen D, et al. Financial implications of avapritinib for treatment of unresectable gastrointestinal stromal tumors in patients with a *PDGFRA* exon 18 variant or after 3 previous therapies in a hypothetical US health plan. *JAMA Netw Open*. 2020;3(11):e2025866. doi:10.1001/jamanetworkopen.2020.25866

eTable. Weighted Postprogression Cost by Line

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable. Weighted Postprogression Cost by Line

	Duration, Months ^{24,a}	Proportion of Time in Post-Progression, %	Monthly Post-Progression Cost, \$	Weighted Post-Progression Cost, \$
<i>GIST with Exon 18 Mutations</i>				
2L Treatment	2.6	9	8,955	829
3L Treatment	5.6	20	12,134	2,418
4L Treatment ^b	19.9	71	176	125
Total	28.1	100	n/a	3,371
<i>GIST - 4L Treatment</i>				
5L+ Treatment ^b	Until death	100	176	176

Abbreviations: 2L, second-line of therapy; 3L, third-line of therapy; 4L, fourth-line of therapy; BCS, best supportive care.

^a Duration of treatment in 2L, 3L uses median progression-free survival from von Mehren et al. 2018.²⁴

^b Treatment for Exon 18 patients after progression in 3L is assumed to be BSC. BSC is assumed not to involve pharmaceutical treatment, with no adverse events, but is assumed to have an ongoing monitoring cost similar to monitoring cost for active drug treatment.